Idiopathic pulmonary fibrosis remains a relevant problem of the healthcare system with an unfavorable prognosis for patients due to progressive fibrous remodeling of the pulmonary parenchyma. Starting with the damage of the epithelial lining of alveoli, pulmonary fibrosis is implemented through a cascade of complex mechanisms, the crucial of which is the TGF-β/SMAD-mediated pathway, involving various cell populations. Considering that a number of the available drugs (pirfenidone and nintedanib) have only limited effectiveness in slowing the progression of fibrosis, the search and justification of new approaches aimed at regulating the immune response, cellular aging processes, programmed cell death, and transdifferentiation of cell populations remains relevant. This literature review presents the key modern concepts concerning molecular genetics and cellular mechanisms of lung fibrosis development, based mainly on in vitro and in vivo studies in experimental models of bleomycin-induced pulmonary fibrosis, as well as the latest data on metabolic features, potential targets, and effects of vitamin D and its metabolites.
Background — According to the data from the published sources worldwide, about 10% of the world population suffers from osteoarthrosis. While searching for novel methods of osteoarthrosis treatment, we proposed administering intra-articular injections of autologous platelet-rich plasma. The goal of this clinical study was to evaluate the effectiveness of autologous platelet-rich plasma injections in osteoarthrosis patient treatment. Methods — This open-label parallel-group study was a pilot randomized controlled trial. An analysis of the treatment outcomes for 128 patients with knee joint arthrosis was performed. All patients were split among three groups, and subjects in two of those were receiving conventional treatment. Clinical efficacy was calculated from pain intensity, determined using Visual Analog Scale, Lequesne index and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Inflammatory response intensity was assessed by superoxide dismutase content and erythrocyte catalase activity. Results — It was demonstrated that administering platelet-rich plasma allowed achieving tangible clinical and laboratory results without any side effects and with very few contraindications. The latter included, for instance, blocking inflammatory process in the joints, thereby inhibiting the oxidative stress, which is the most pathogenetically substantiated treatment of osteoarthrosis. Conclusion — Thus, we have discovered that platelet-rich plasma injections had apparent anti-inflammatory and pain-relieving effects, along with inhibiting action of destructive processes in the cartilaginous tissue, hence improving life quality of the patients with osteoarthrosis.
1 January 2018 in S.S. Korsakov Journal of Neurology and Psychiatry
Leiomyomatosis peritonealis disseminata (LPD) is a benign disease characterized by the presence of multiple small nodules on the omentum, parietal, and visceral peritoneum. It corresponds to leiomyoma and often resembles metastases of malignant tumors; however, with favorable prognosis. Here we describe a 46-year-old woman, diagnosed with LPD, to demonstrate the etiopathogenesis of the developed leiomyomatosis following endoscopic extirpation of the uterus with the use of a power morcellator. The patient was operated for diffuse leiomyoma using a power morcellator. Six months later, during a follow-up visit, disseminated tumornodes on the peritoneum were revealed. Histological and immunohistochemical (smooth muscle a-actin, vimentin, estrogen receptors, progesterone receptors, and Ki67) study confirmed the diagnosis of LPD. As part of the follow-up, certain regression of the tumor nodes was noted against the backdrop of the onset of menopause and the corresponding decline of estrogen levels. Currently, the prognosis is favorable and follow-up is ongoing. Such cases are rare, but the condition is particularly important due to its iatrogenic nature. It has attracted the attention of the Food and Drug Administration (FDA) because power morcellation is probably associated with the risk of spreading suspected cancerous tissue. The existing high risk of iatrogenic LPD formation indicates the need for detailed reporting of all similar clinical cases, including the established pathogenetic and pathomorphological mechanisms of this process to prevent morcellator-related complications.